Aberrant Expression of MicroRNA-15a and MicroRNA-16 Synergistically Associates with Tumor Progression and Prognosis in Patients with Colorectal Cancer

Table 1

Associations of miR-15a and/or miR-16 expression with the clinicopathological characteristics of colorectal cancer.

Clinical features	Case number (%)	miR-15a-low		miR-16-low		miR-15a-low/miR-16-low
		(, %)		(, %)		(, %)
Gender
Male	76 (60.32)	42 (55.26)	NS	45 (59.21)	NS	32 (42.11)	NS
Female	50 (39.68)	31 (62.00)		31 (62.00)		21 (42.00)
Age (years)
<66	48 (30.10)	32 (66.67)	NS	32 (66.67)	NS	22 (45.83)	NS
≥66	78 (69.90)	41 (52.56)		44 (56.41)		31 (39.74)
Site of primary tumor
Right-sided	48 (38.10)	30 (62.50)	NS	30 (62.50)	NS	22 (45.83)	NS
Left-sided	46 (36.51)	26 (56.52)		26 (56.52)		20 (43.48)
Rectum	32 (25.40)	17 (53.13)		20 (62.50)		11 (34.38)
Tumor size (cm)
<5	70 (55.56)	42 (60.00)	NS	42 (60.00)	NS	32 (45.71)	NS
≥5	56 (44.44)	31 (55.36)		34 (60.71)		21 (37.50)
Depth of tumor invasion
T1-T2	47 (37.30)	30 (63.83)	NS	30 (63.83)	NS	20 (42.55)	NS
T3-T4	79 (62.70)	43 (54.43)		46 (58.23)		33 (41.77)
Lymph node metastasis
Negative	68 (53.97)	29 (42.65)	0.01	29 (42.65)	0.01	13 (19.12)	0.008
Positive	58 (46.03)	44 (75.86)		47 (81.03)		40 (68.97)
TNM stage
I	13 (10.32)	3 (23.08)	0.001	3 (23.08)	0.001	0 (0)	<0.001
II	46 (36.51)	17 (36.96)		20 (43.48)		10 (18.87)
III	50 (39.68)	36 (72.00)		36 (72.00)		26 (52.00)
IV	17 (13.49)	17 (100.00)		17 (100.00)		17 (100.00)
Histological grade
Well/moderately	80 (63.49)	40 (50.00)	0.02	40 (50.00)	0.02	23 (28.75)	0.01
Poorly	46 (36.51)	33 (71.74)		36 (78.26)		30 (65.22)

Note: “NS” refers to the difference without statistical significance.